Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8384MR)

This product GTTS-WQ8384MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ8384MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9884MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ9705MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ369MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ10598MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ1148MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ13480MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ8075MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ8383MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aTROP2S7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW